Ampiox-Tsiteli A

Severe course of infections (sepsis, endocarditis, pneumonia, postpartum infection, etc.), especially in newborns and premature infants (infection of the amniotic fluid, respiratory disorders of the newborn, requiring measures to revive, the risk of aspiration pneumonia, etc.), lung infections, respiratory tract infections, angina, cholangitis, cholecystitis, kidney infections, including pyelitis, skin, infected burns and wounds, prevention of infectious postoperative complications, prevention and treatment of infections in children, gonorrhea (with resistance to benzylpenicillin).

.tsch. against the background of immunodeficiency) and infections in newborns (infection of the amniotic fluid, the risk of aspiration pneumonia)

I / m or I / v (jet or drip). Adults and children over 14 years of age in a single dose of 0.5-1 g, daily dose-2-4 g, newborns, premature infants and children under 1 year-0.1–0.2 g/kg / day, children from 1 year to 7 years-0.1 g/kg/day, from 7 to 14 years-0.05 g/kg/day in 3-4 doses at intervals of 6-8 hours. In severe infections, you can increase the dose by 1.5-2 times.

The solution for intravenous administration is prepared ex tempore, adding 2-5 ml of water for injection to the contents of the bottle. The course of treatment with intravenous administration - from 5-7 days to 3 weeks.

For intravenous jet administration, a single dose for adults is dissolved in 10-15 ml of water for injection or isotonic sodium chloride solution, administered slowly for 2-3 minutes. For intravenous drip administration, a single dose is dissolved in 100-200 ml of isotonic sodium chloride solution or 5-10% glucose solution, administered at a rate of 60-80 drops / min. For intravenous drip administration to children, 5-10% glucose solution (30-100 ml, depending on age) is used as a solvent. Solutions should be administered immediately after preparation. The course of treatment with intravenous administration is 5-7 days, then (if necessary) switch to intravenous injections

Inside, a single dose for adults and children over 14 years of age-0.5-1 g, daily-2-4 g (the daily dose is divided into 4-6 doses). Children 3-7 years — 100 mg / kg / day, 7-14 years-50 mg/kg / day. The duration of treatment is from 5-7 days to 2 weeks.

I / m or I /v (jet or drip at a speed of 60-80 drops / min). Single dose for adults and children over 14 years — 0.5-1 g, daily dose-2-4 g, newborns, premature infants and children under 1 year — 100-200 mg / kg / day, 1-7 years-100 mg/kg/day, 7-14 years-50 mg/kg / day. The daily dose is administered in 3-4 doses, with an interval of 6-8 hours. In severe infection, these doses are increased by 1.5-2 times. The maximum daily dose for an adult is 8 g. The duration of treatment is from 5-7 days to 2 weeks. The drug is administered within 5-7 days, followed by a transition (if necessary) to an intravenous injection.

For intravenous administration, the contents of the vial (0.2 and 0.5 g) are dissolved, respectively, in 2 and 5 ml of water for injection. For intravenous drip administration to adults, a single dose is dissolved in 100-200 ml of isotonic sodium chloride solution or 5-10% glucose solution. For drip administration to children, 5-10% glucose solution (30-100 ml, depending on age) is used as a solvent. Solutions are used immediately after preparation (adding other drugs to the prepared solution is unacceptable).

Hypersensitivity, infectious mononucleosis, lymphocytic leukemia.

Hypersensitivity to drugs of the penicillin group and other beta-lactam antibiotics, infectious mononucleosis, lymphocytic leukemia.

From the cardiovascular system and blood (hematopoiesis, hemostasis): leukopenia, neutropenia, anemia.

From the gastrointestinal tract: nausea, vomiting, diarrhea, dysbacteriosis, taste changes, pseudomembranous enterocolitis.

Allergic reactions: skin rash, urticaria, Quincke's edema, rhinitis, conjunctivitis, fever, rarely-anaphylactic shock.

Other: arthralgia, eosinophilia, superinfection, pain at the site of the/m injection, phlebitis and periflebit (at/in the introduction).

Allergic reactions (urticaria, skin hyperemia, skin rash, Quincke's edema, rhinitis, conjunctivitis, fever, arthralgia, eosinophilia, anaphylactic shock), dysbacteriosis, taste change, vomiting, nausea, diarrhea, pseudomembranous enterocolitis, leukopenia, neutropenia, anemia. With intravenous administration of Ampiox-Tsiteli Aa-sodium, phlebitis and periflebitis may develop, with intravenous administration-soreness at the injection site.

After the IV injection of C_max it is achieved after 0.5-1 h, after the intravenous administration, a plasma concentration is quickly created that exceeds that of the intravenous method of administration. It is excreted from the body by the kidneys, partially with bile, does not accumulate.

The components of the drug when taken orally penetrate well into the blood. C_max in the blood, they are observed after oral administration in 1.5-2 hours, after intravenous administration - in 0.5-1 hours, with intravenous administration, high concentrations are quickly created in the blood, exceeding those observed with intravenous administration. Both antibiotics are excreted by the kidneys, partly with bile, and penetrate into breast milk. With repeated injections, they do not accumulate.

Weakens the effect of oral estrogens-containing drugs, strengthens-indirect anticoagulants. Probenecid, diuretics, allopurinol, phenylbutazone, etc. NSAIDs increase the plasma concentration and the risk of side effects. Bactericidal antibiotics have a synergistic effect, bacteriostatic — antagonistic.

Antacids, glucosamine, laxatives, aminoglycosides, food slow down and reduce the absorption of Ampiox-Tsiteli Aa, ascorbic acid-increases. Bactericidal antibiotics (in tons.tsch. aminoglycosides, cephalosporins, cycloserine, vancomycin, rifampicin) have a synergistic effect, bacteriostatic drugs (macrolides, chloramphenicol, lincosamides, tetracyclines, sulfonamides) - antagonistic. Ampiox-Tsiteli A increases the effectiveness of indirect anticoagulants (suppresses the intestinal flora, reduces the synthesis of vitamin K and prothrombin index), reduces the effectiveness of oral contraceptives, drugs, during the metabolism of which paraaminobenzoic acid is formed, ethinyl estradiol (the risk of breakthrough bleeding). Diuretics, allopurinol, phenylbutazone, NSAIDs, probenecid-increase the concentration, reducing tubular secretion. Allopurinol increases the risk of developing a skin rash